Natera, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6323071042
USD
198.38
0.7 (0.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.14 M

Shareholding (Dec 2025)

FII

13.98%

Held by 356 FIIs

DII

39.81%

Held by 61 DIIs

Promoter

1.56%

How big is Natera, Inc.?

22-Jun-2025

As of Jun 18, Natera, Inc. has a market capitalization of $22.88 billion, with net sales of $1.83 billion and a net profit of -$189.76 million over the last four quarters. The company reported shareholder's funds of $1.20 billion and total assets of $1.69 billion as of Dec 24.

Market Cap: As of Jun 18, Natera, Inc. has a market capitalization of 22,878.38 million, classifying it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Natera, Inc. reported net sales of 1,831.00 million and a net profit of -189.76 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,195.42 million and total assets of 1,686.40 million.

View full answer

What does Natera, Inc. do?

22-Jun-2025

Natera, Inc. is a mid-cap diagnostics company specializing in genetic testing services, with recent net sales of $502 million and a net loss of $67 million. The company has a market cap of approximately $22.88 billion and does not pay dividends.

Overview:<BR>Natera, Inc. is a diagnostics company engaged in the discovery, development, and commercialization of genetic testing services within the Pharmaceuticals & Biotechnology industry, categorized as a mid-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 502 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -67 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 22,878.38 Million (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.73<BR>- Return on Equity: -15.31%<BR>- Price to Book: 18.46<BR><BR>Contact Details:<BR>- Address: 201 Industrial Rd Ste 410, SAN CARLOS CA: 94070-2396<BR>- Tel: ['1 650 2499090', '1 650 2499091']<BR>- Fax: 1 302 6745266<BR>- Website: http://www.natera.com

View full answer

Should I buy, sell or hold Natera, Inc.?

22-Jun-2025

Who are in the management team of Natera, Inc.?

22-Jun-2025

As of March 2022, Natera, Inc.'s management team includes Dr. Matthew Rabinowitz (Executive Chairman), Mr. Steven Chapman (CEO), Mr. Jonathan Sheena (CTO), and several independent directors, including Roelof Botha and Dr. Monica Bertagnolli. This team provides strategic direction and governance for the company.

As of March 2022, the management team of Natera, Inc. includes the following individuals:<BR><BR>- Dr. Matthew Rabinowitz: Executive Chairman of the Board, Co-Founder<BR>- Mr. Steven Chapman: President, Chief Executive Officer, Director<BR>- Mr. Jonathan Sheena: Co-Founder, Chief Technology Officer, Director<BR>- Mr. Roelof Botha: Lead Independent Director<BR>- Mr. Roy Baynes: Independent Director<BR>- Dr. Monica Bertagnolli: Independent Director<BR>- Dr. Rowan Chapman: Independent Director<BR>- Mr. Todd Cozzens: Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

View full answer

Is Natera, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Natera, Inc. shows a mildly bullish trend with strong weekly indicators and solid performance, having outperformed the S&P 500 over the past year and three years, despite mixed signals from different time frames.

As of 3 October 2025, the technical trend for Natera, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish for both weekly and monthly periods, and the daily moving averages are also bullish. However, the weekly Dow Theory shows a mildly bearish stance, contrasting with the monthly Dow Theory, which is mildly bullish. <BR><BR>In terms of performance, Natera has outperformed the S&P 500 over the past year with a return of 31.22% compared to the S&P 500's 17.82%, and significantly over the past three years with a return of 262.28% versus 82.57%. Overall, the current technical stance is mildly bullish, driven by strong weekly indicators and solid multi-period returns.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

The company has declared Positive results for the last 8 consecutive quarters

  • OPERATING CASH FLOW(Y) Highest at USD 194.3 MM
  • NET PROFIT(HY) Higher at USD -188.48 MM
  • DEBTORS TURNOVER RATIO(HY) Highest at 7.14 times
2

Risky -

3

Reducing Promoter Confidence

4

Consistent Returns over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 28,017 Million (Mid Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.76

stock-summary
Return on Equity

-24.69%

stock-summary
Price to Book

22.37

Revenue and Profits:
Net Sales:
665 Million
(Quarterly Results - Dec 2025)
Net Profit:
47 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.02%
0%
-12.02%
6 Months
13.08%
0%
13.08%
1 Year
32.92%
0%
32.92%
2 Years
121.6%
0%
121.6%
3 Years
250.31%
0%
250.31%
4 Years
428.87%
0%
428.87%
5 Years
87.15%
0%
87.15%

Natera, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
42.37%
EBIT Growth (5y)
-57.80%
EBIT to Interest (avg)
-38.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
1.19
Tax Ratio
0.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.37
EV to EBIT
-76.93
EV to EBITDA
-86.02
EV to Capital Employed
89.02
EV to Sales
12.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-115.71%
ROE (Latest)
-24.69%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 125 Schemes (44.61%)

Foreign Institutions

Held by 356 Foreign Institutions (13.98%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 39.78% vs 53.04% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 187.92% vs 31.03% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "665.50",
          "val2": "476.10",
          "chgp": "39.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.80",
          "val2": "-56.90",
          "chgp": "91.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.30",
          "chgp": "-23.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.30",
          "val2": "-53.80",
          "chgp": "187.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-28.40%",
          "val2": "-136.00%",
          "chgp": "10.76%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 35.90% vs 56.74% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -9.35% vs 56.21% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,306.10",
          "val2": "1,696.90",
          "chgp": "35.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-262.50",
          "val2": "-191.30",
          "chgp": "-37.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.10",
          "val2": "10.70",
          "chgp": "-61.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-208.20",
          "val2": "-190.40",
          "chgp": "-9.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-132.70%",
          "val2": "-131.00%",
          "chgp": "-0.17%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoYstock-summary

Dec'25
Dec'24
Change(%)
Net Sales
665.50
476.10
39.78%
Operating Profit (PBDIT) excl Other Income
-4.80
-56.90
91.56%
Interest
1.00
1.30
-23.08%
Exceptional Items
-3.90
0.00
Consolidate Net Profit
47.30
-53.80
187.92%
Operating Profit Margin (Excl OI)
-28.40%
-136.00%
10.76%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Dec 2025 is 39.78% vs 53.04% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 187.92% vs 31.03% in Dec 2024

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
2,306.10
1,696.90
35.90%
Operating Profit (PBDIT) excl Other Income
-262.50
-191.30
-37.22%
Interest
4.10
10.70
-61.68%
Exceptional Items
-3.90
0.00
Consolidate Net Profit
-208.20
-190.40
-9.35%
Operating Profit Margin (Excl OI)
-132.70%
-131.00%
-0.17%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 35.90% vs 56.74% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -9.35% vs 56.21% in Dec 2024

stock-summaryCompany CV
About Natera, Inc. stock-summary
stock-summary
Natera, Inc.
Pharmaceuticals & Biotechnology
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father(s).
Company Coordinates stock-summary
Company Details
201 Industrial Rd Ste 410 , SAN CARLOS CA : 94070-2396
stock-summary
Tel: 1 650 24990901 650 2499091
stock-summary
Registrar Details